A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme

Human Gene Therapy

Volumn 11, Issue 17, 2000, Pages 2389-2401

  Rainov, N G ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE THERAPY; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROSURGERY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETROVIRUS; TREATMENT OUTCOME; BRAIN TUMOR; GENETICS; HERPES SIMPLEX VIRUS 1; METHODOLOGY; MIDDLE AGED; MORTALITY; SURGERY; SURVIVAL RATE;

BRAIN NEOPLASMS; FEMALE; GANCICLOVIR; GENE THERAPY; GLIOBLASTOMA; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MIDDLE AGED; SURGERY; SURVIVAL RATE; THYMIDINE KINASE;

EID: 0034694011     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303400750038499     Document Type: Article

References (42)

1. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors
2. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV Tk retroviral gene therapy
3. Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy
4. Enhanced expression of thymidine kinase in human cells following ionizing radiation
5. Incidence of risk of thromboembolism during treatment of high-grade gliomas: A prospective study
6. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
7. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats
8. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene
9. The basis for current: Treatment recommendations for malignant gliomas
10. The 'bystander effect': Tumour regression when a fraction of the tumour mass is genetically modified
11. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: A gene-marking and neuropathological study
12. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
13. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas
14. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells; transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
15. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
16. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer
17. Long-term rat survival after malignant brain tumour regression by retroviral gene therapy
18. Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir
19. A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma
20. Histological typing of tumors of the central nervous system
21. Acute neurologic dysfunction associated with high-dose chemotherapy and autologous bone marrow rescue for primary malignant brain tumors
22. Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy
23. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion
24. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells
25. Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy
26. An improved retroviral vector encoding the herpes simplex virus thymidine kinase gene increases antitumor efficacy in vivo
27. Conditionally replicating herpes simplex virus mutant. G207 for the treatment of malignant glioma: Results of a phase I trial
28. The biology of malignant gliomas: A comprehensive survey
29. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
30. Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses
31. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration
32. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: A pilot study in humans
33. Chemotherapy of brain tumors
34. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir program
35. Systemic and local immune response against retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme
36. In situ retroviral-mediated gene transfer for the treatment of brain tumours in rats
37. Therapy of malignant brain tumours by intratumoral implantation of retroviral vector-producing cells
38. Molecular biology and neurosurgery in the third millennium
39. 'Bystander killing' induces apoptosis and is inhibited by forskolin
40. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumour transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
41. Biology and treatment of malignant glioma
42. Generation of an anti-tumour immune response in a non-immunogenic tumor: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression